CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
CytomX Therapeutics (CTMX) has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. markets close. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. Investors can access the webcast through CytomX's investor relations website, and an archived version will be available afterward.
CytomX Therapeutics (CTMX) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 giovedì 7 novembre 2024, dopo la chiusura dei mercati statunitensi. L'azienda terrà una conference call e una trasmissione in webcast alle 17:00 ET / 14:00 PT per discutere i risultati. Gli investitori possono accedere al webcast tramite il sito web delle relazioni con gli investitori di CytomX, e una versione archiviata sarà disponibile successivamente.
CytomX Therapeutics (CTMX) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre de 2024, después del cierre de los mercados estadounidenses. La compañía llevará a cabo una llamada de conferencia y una transmisión web a las 5:00 p.m. ET / 2:00 p.m. PT para discutir los resultados. Los inversores pueden acceder a la transmisión a través del sitio web de relaciones con inversores de CytomX, y una versión archivada estará disponible posteriormente.
CytomX Therapeutics (CTMX)는 2024년 3분기 재무 결과를 2024년 11월 7일 목요일, 미국 시장이 마감된 후에 발표할 것이라고 발표했습니다. 회사는 결과에 대해 논의하기 위해 오후 5시(ET) / 오후 2시(PT)에 컨퍼런스 콜 및 웹캐스트를 진행합니다. 투자자들은 CytomX의 투자자 관계 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 이후 아카이브 버전도 제공될 예정입니다.
CytomX Therapeutics (CTMX) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le jeudi 7 novembre 2024, après la fermeture des marchés américains. L'entreprise organisera une conférence téléphonique et un webinaire à 17h00 ET / 14h00 PT pour discuter des résultats. Les investisseurs peuvent accéder au webinaire via le site web des relations avec les investisseurs de CytomX, et une version archivée sera disponible par la suite.
CytomX Therapeutics (CTMX) hat bekannt gegeben, dass es seine finanziellen Ergebnisse für das dritte Quartal 2024 am Donnerstag, den 7. November 2024, nach Schließung der US-Märkte veröffentlichen wird. Das Unternehmen wird um 17:00 Uhr ET / 14:00 Uhr PT eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen. Investoren können über die Investor-Relations-Website von CytomX auf den Webcast zugreifen, und eine archivierte Version wird anschließend verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report third quarter financial results on Thursday, November 7, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. An archived replay of the webcast will be available on the Company’s website.
Audio Conference Call:
| U.S. Dial-in Number: | (800) 715-9871 | ||
| International Dial-in Number: | (646) 307-1963 | ||
| Conference ID: | 5171678 | ||
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-2051 was discovered in collaboration with Immunogen, now part of AbbVie. CX-801 is an interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
When will CytomX Therapeutics (CTMX) report Q3 2024 earnings?
How can investors access CytomX Therapeutics' (CTMX) Q3 2024 earnings call?
What time is CytomX Therapeutics' (CTMX) Q3 2024 earnings call?
